1. A method for diagnosing non-small cell lung cancer in humans, comprising measuring in a human blood sample a level of autoantibodies selected from a group of autoantibodies that recognize mutant human EGFR, where an elevated level of said autoantibody is selected from a group of autoantibodies that recognize mutant human EGFR in a human blood sample compared with the level of the indicated autoantibody characteristic of a person from a healthy population, indicates non-small cell lung cancer, and the level of autoantibody in the sample human blood is 5 times higher than the level of autoantibodies characteristic of a healthy person populyatsii.2. The method of claim 1, wherein the autoantibody recognizes a mutant EGFR peptide selected from the group consisting of Seq. Id. No. 554, Seq. Id. No. 555, Seq. Id. No. 556, Seq. Id. No. 557, Seq. Id. No. 558, Seq. Id. No. 559 and Seq. Id. No. 560.3. The use of autoantibodies to predict the response of a patient suffering from NSCLC to treatment with erlotinib or a pharmaceutically acceptable salt thereof, in particular erlotinib hydrochloride, wherein the antibody is identified using the method of claim 1.4. A method for diagnosing non-small cell lung cancer in humans, comprising: measuring a level of autoantibodies in a human blood sample selected from a group of autoantibodies that recognize human EGFR, where an elevated level of said autoantibodies selected from a group of autoantibodies that recognize mutant human EGFR in a human blood sample by compared with the level of the indicated autoantibody, characteristic of a person from a healthy population, indicates non-small cell lung cancer, and the level of autoantibody in the human blood sample century is 5 times higher than the level of autoantibody characteristic of a person from a healthy population. 5. The method of claim 4,1. Способ диагностики немелкоклеточного рака легких у человека, включающийизмерение в образце крови человека уровня аутоантитела, выбранного
